EPFL Innovation Park Building B
+41 21 345 91 21
+41 21 345 91 20
Contact Person Function:
AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as Alzheimer’s disease. The Company’s pipeline features seven therapeutic and three diagnostic product candidates. The most advanced of these is crenezumab, an anti-Abeta antibody in Phase 3 clinical studies, which is being advanced by our collaboration partner Genentech, Inc., a member of the Roche group. Other business partners include Biogen, Janssen Pharmaceuticals, Nestlé Institute of Health Sciences and Piramal Imaging.
Year of Foundation:
Persons employed in Switzerland:
How many in Biotechnology:
Key Business in Switzerland:
Pharmaceuticals / Therapeutics / Vaccines (human)
Research & Development:
Four clinical programs and broad preclinical portfolio: Crenezumab (anti-Abeta antibody in AD, Phase 3 and Phase 2 prevention trial, partnered with Genentech) ACI-24 (anti-Abeta vaccine in AD, Phase1/2a), ACI-35 (anti-pTau vaccine in AD, Phase 1), ACI-24 (anti-Abeta vaccine in Down syndrome, Phase 1), Anti-Tau antibody (Phase 1, partnered with Genentech), Morphomer Tau (Tau inhibitor in AD, pre-clinic, Tau- PET imaging agent (partnered with Piramal Imaging, pre-clinic), alpha-synuclein Tau imaging agent (partnered with Biogen, pre-clinic), IVD (Tau, Abeta, pre-clinic), Morphomer Abeta (Abeta inhibitor, Glaucoma, pre-clinic), Morphomer alpha-Syn (alpha-synuclein inhibitor, Parkinson\'s disease, pre-clinic)
The core business of AC Immune is the development of innovative drugs for the treatment of Alzheimer’s Disease and diseases involving misfolding of proteins. Our expertise and proprietary cutting edge technologies enable us to support research and enhance the discovery of new molecules. In order to maximize the value of our innovative therapeutics, partnering with leading pharmaceutical companies is a key element of our business strategy.